The maintenance of FOXP3 expression in CD25 hi regulatory T cells (Tregs) is crucial to the control of inflammation and essential for successful Treg transfer therapies. Coexpression of CD25 and FOXP3 in combination with a hypomethylated region within the FOXP3 gene, called the Treg-specific demethylated region (TSDR), is considered the hallmark of stable Tregs. The TSDR is an epigenetic motif that is important for stable FOXP3 expression and is used as a biomarker to measure Treg lineage commitment.
+ Tregs have been intensively studied, given their critical roles in regulating immune responses. Before the discovery of FOXP3, high levels of the IL-2 receptor a-chain, CD25 (2), had been relied upon as a marker of T cells with regulatory potential. However, CD25 is not unique to Tregs because T conventional cells (Tcons) upregulate this receptor upon activation. Early studies of FOXP3 (1, 3, 4) demonstrated that the highest CD25-expressing cells were also predominantly FOXP3 hi , and therefore Tregs were defined by high coexpression of CD25 and FOXP3.
A key paradox often encountered in studies of autoimmune disease, exemplified by childhood arthritis (Juvenile Idiopathic Arthritis [JIA]) (5, 6) , is the enrichment of FOXP3 + T cells at the inflamed site. This raises the question as to why disease persists despite the enhanced Treg frequency. Several studies have demonstrated that human Tcons upregulate FOXP3 upon activation (7) (8) (9) , suggesting that, theoretically, any observed CD25 hi FOXP3
hi T cell population could contain activated Tcons (9) , as well as Tregs. Work by several groups has shown that epigenetic modifications to the FOXP3 promoter (10) and intronic enhancer (11, 12) can distinguish Tregs from Tcons. The intronic enhancer region, which has been called the Tregspecific demethylated region (TSDR), is an excellent discriminator between Tregs and promiscuous FOXP3-expressing T cells, and it can be used as a biomarker to quantify Tregs (13) . Activated Tcons, TGF-b-induced Tregs, and naive T cells all display methylation of this region. TSDR status can therefore distinguish between a CD25 hi FOXP3
hi activated Tcon and a fully committed CD25 hi FOXP3 hi Treg, and, theoretically, could also be used to identify Tregs that may have recently lost FOXP3 expression. The terms Treg, FOXP3, and/or CD25 hi are sometimes used interchangeably; however, to what extent these markers identify bona fide Tregs at chronically inflamed sites in humans is unknown, and the temporal dynamics of FOXP3 and/or CD25 ex-pression at inflamed sites are poorly understood. Furthermore, functional studies are often hindered in humans because Tregs must be isolated through surrogate cell surface marker expression, for example, CD25 and CD127 (14) . We have previously reported that CD25 and FOXP3 expression are frequently dissociated in the synovial fluid (SF) of JIA patients (6) , raising questions about the extent and stability of Tregs at the inflamed site. We reveal that hypomethylation at the TSDR is decoupled from stable FOXP3 expression in a subset of CD25 hi T cells. This population represents a Treg subset that has very low FOXP3 expression, is proportionally increased in the more severe forms of arthritis, and displays defects in pathways important for Treg homeostasis. Our data suggest that the presence of TSDR hypomethylation is not sufficient in itself to ensure FOXP3 expression.
Materials and Methods

Human samples and cells
Blood samples were obtained from 11 healthy adult volunteers and 4 healthy children, all with no known autoimmune or genetic conditions. Forty-one patients with JIA (14 male, 27 female), all fulfilling the International League of Associations for Rheumatology classification criteria (15) , were included in this study. Four patients gave only PBMC samples and seven provided both PBMC and SF mononuclear cell (SFMC) samples. Seven patients contributed more than one SF sample. See Supplemental Table I for detailed patient characteristics.
For disease severity analysis, 45 SF samples were analyzed, of which 18 were from patients with the persistent oligoarticular subtype, 16 with extended oligoarticular JIA, and 11 with polyarticular JIA. For clinical severity analysis, the patient's diagnosis at the time of sampling was identified (including seven patients with serial samples); the polyarticular and extended oligoarticular patient samples were combined as a group because all had more than five joints involved, that is, polyarticular course of disease (more severe, n = 27, 70.4% female), and they were compared with the patient samples identifying with the mild remitting persistent oligoarticular JIA subtype (n = 18, 61.1% female).
SFMCs and PBMCs were prepared by density gradient centrifugation using LymphoPrep (Axis-Shield) with SF samples undergoing pretreatment with hyaluronidase (10 U/ml; Sigma-Aldrich) (6) .
Flow cytometry and cell sorting
Flow cytometry was performed with the following directly conjugated Abs: CD3 (clone UCHT1) V450/V500 (both BD Biosciences); CD3-PC7 (Beckman Coulter); CD4-FITC (RPA-T4) (eBioscience); CD4 (clone OKT4)-BV711 (BioLegend); CD4 (clone SFCI12T4D11)-PC7 (Beckman Coulter); CD4 (clone S3. ; ubiquitin-specific peptidase 7 (USP7; polyclonal) unconjugated (Bethyl Laboratories) or goat anti-rabbit Alexa Fluor 488 for USP7 detection using standard techniques (see Ref. 16 ). CTLA-4 staining was performed intracelluarly using the eBioscience FOXP3 staining buffers. Cytokine staining was performed after 2 h of stimulation with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence of 5 mg/ml brefeldin A (all Sigma-Aldrich) before fixation and staining for IL-17A and IL-2 using eBioscience FOXP3 staining buffers. Cell sorting was performed on a FACSAria machine after preenrichment of CD4 + T cells by immunomagnetic negative selection (StemCell Technologies).
For sorting of cells based on FOXP3 staining, after CD4 + T cell enrichment, cells were stained with Live/Dead fixable blue dead cell stain followed by labeling at 4˚C with CD4, CD127, and CD25 Abs. Cells were then fixed for 30 min using 1 ml FOXP3 Fix/Perm reagent (eBioscience) before washing and labeling with allophycocyanin-conjugated anti-FOXP3 (clone 236A/E7) for 45 min. 
Detection of phosphorylated STAT5 by flow cytometry
Cryopreserved SFMCs were thawed, washed, and resuspended in plain RPMI 1640 at a density of 5 3 10 6 /ml in FACS tubes (BD Biosciences). Cells were incubated for 15 min at 37˚C before stimulation with 100 U/ml recombinant human IL-2 (Roche) for 15 min. Stimulation was stopped by the addition of paraformaldehyde to a final concentration of 1.5% and a further incubation at 37˚C for 15 min. Cells were pelleted, permeablized in 90% ice-cold methanol for 15 min on ice, followed by two washes with PBS and one wash with PBS/2.5% FBS. Cells were then stained for 40 min at 4˚C with Abs to CD3, CD4, CD25, FOXP3, and p-STAT5.
DNA extraction
For isolation of DNA from live, unfixed cells, a Qiagen DNeasy blood and tissue kit was used. For isolation of DNA from fixed and permeablized cells, a published protocol was used with minor modifications (17) . Sorted cells were incubated with 300 ml lysis buffer (10 mM Tris-HCl, 100 mM NaCl, 50 mM EDTA, 0.5% SDS, 0.1 mg/ml proteinase K [Roche], and 20 mg/ml RNase A [Qiagen], pH 8.0) for 24 h at 60˚C on a thermo-shaker. The lysis solution was mixed vigorously with one volume of phenol/chloroform/ isoamyl alcohol (25:24:1; Sigma-Aldrich) and the phases were separated by centrifugation at 13,000 rpm for 5 min at room temperature. The aqueous phase was removed and mixed with one volume of chloroform/isoamyl alcohol (24:1), phases were separated by centrifugation at 13,000 rpm for 5 min at room temperature, and the aqueous phase was removed and DNA precipitated by addition of ethanol to a final concentration of 75%. Tubes were incubated at 220˚C for at least 4 h, before DNA was pelleted and washed twice with 70% ethanol. DNA pellets were air-dried before dissolving in TE buffer (Sigma-Aldrich), pH 8.0, for at least 24 h at room temperature.
Bisulfite treatment and methylation analysis
Male patients (patients 5, 9, 24, and 28) were chosen for TSDR analysis, and patients 24 and 28 were chosen for promoter analysis. DNA was bisulfite treated using the EpiTect bisulfite kit (Qiagen). A 336-bp segment containing the TSDR of FOXP3 was amplified (FOXP3 TSDR, forward, 59-TGT TTG GGG GTA GAG GAT TT-39, reverse, 59-TAT CAC CCC ACC TAA ACC AA-39) (11) or the FOXP3 promoter (FOXP3 promoter, forward, 59-TGG TGA AGT GGA TTG ATA GAA AAG G-39, reverse, 59-TAT AAA AAC CCC TCC CCA CC-39) (10) by platinum high-fidelity Taq (Invitrogen), followed by cloning of PCR products (TOPO TA kit). Clones were sequenced using M13 primers, and sequences were aligned (reverse complementation was accepted) to an imputed TSDR/promoter sequence using Geneious Pro 5.6.6 software (Biomatters). The retention of a C nucleotide at the CpG position identified methylated CpG sites; the presence of a T nucleotide identified unmethylated CpGs. The percentage of clones displaying methylated CpG for each site, as well as total average, was then determined. For TSDR analysis, a mean of 21-24 clones per subset per patient was performed.
In vitro Treg suppression assays
To assess proliferation of Tcons, Tcons (CD4
lo ) were labeled in 1 mM CFSE solution as previously described (see Ref. 18) . Labeled Tcons were cultured at a constant number of 5 3 10 4 /well either alone (1:0) or at a 1:2, 1:4, and, where cell numbers permitted, 1:8 ratio with either P2-enriched Tregs or P3-enriched Tregs on V-bottom 96-well plates (Costar) precoated with 1 mg/ml anti-CD3 (clone UCHT1, R&D Systems) and 5 mg/ml anti-CD28 (clone CD28.2, BD Biosciences) Abs in culture medium (RPMI 1640 supplemented with 10% FBS and 100 U/ml penicillin/streptomycin) at 37˚C and 5% CO 2 for 4-5 d. Final cell concentration was maintained at 1 3 10 6 /ml. A cytokine multiplex assay was performed as previously described (19) .
In vitro culture of Tcons and TSDR methylation assessment of Tcons
were isolated from healthy control PBMCs and cultured on anti-CD3 (1 mg/ml)-and anti-CD28 (5 mg/ml)-coated 96-well Vbottom plates at a density of 5 3 10 5 T cells/ml in the presence of 100 U/ml recombinant human IL-2. On day 7, cells were harvested, stained for CD4, CD25, and FOXP3, plus Live/Dead fixable blue dead cell stain, and CD25 hi FOXP3
hi and CD25 hi FOXP3 lo CD4 + T cells were sorted on a FACSAria cell sorter. From the sorted populations, DNA was extracted, bisulfite treated, and the TSDR was amplified, cloned, and sequenced as described above.
RNA extraction and RT-PCR analysis
RNA was extracted from sorted cells according to the manufacturer's instructions (TRIzol, Invitrogen) and converted to cDNA as described (see Ref. 18) . Primer sequences were: FOXP3 mRNA, forward, 59-ACC TGG AAG AAC GCC ATC-39, reverse, 59-TGT TCG TCC ATC CTC CTT TC-39; USP7 (20), forward, 59-GCA AGT GCA GAT AGT CGC AGA GGA CC-39, reverse, 59-CCA TGG TCT GAG AGA GGC TCT GAA C-39. Gene expression is displayed relative to GAPDH (Qiagen) using the 2 2DCt method.
SF Treg culture with IL-2 or proteasome inhibitor MG132
P2 and P3 Tregs were enriched as described above and cultured on 96-well Vbottom plates for 24 h in the presence of medium alone, 2 U/ml recombinant human IL-2, DMSO, or 5 mM proteasome inhibitor MG132 (Sigma-Aldrich).
Statistical analysis
Statistical analysis was performed on Prism 5 for Macintosh software (GraphPad Software). For clarity, statistical tests and error bar descriptions are included in the figure legends. A p value ,0.05 was deemed statistically significant. 
Results
Dissociation
The epigenetic footprint of FOXP3
+ Tregs is not limited to the CD25 hi FOXP3 hi T cell compartment
Because T cell activation can elicit FOXP3 expression in Tcons (9), we wanted to determine the frequency of bona fide FOXP3 + Tregs at the inflamed site. Although there is no single, exclusive Treg marker, the methylation status of the TSDR is a widely used test for distinguishing between activated T cells and bona fide Tregs.
SFMCs were stained for the surface markers CD4, CD25, and CD127 and then fixed, permeablized, and stained for FOXP3 before sorting into four subsets ( Fig DNA was extracted from sorted populations before bisulfite treatment for methylation analysis. Complete methylation was seen in the Tcon population (median, 95.45%). However, interestingly, extensive demethylation was not restricted to the P2 population (Fig. 2C, 2D ): the P2 population displayed complete demethylation (median, 3.57%) whereas the P1 population (median, 12.80%) and P3 CD4 + T cells (median, 21.3%) also showed extensive demethylation despite the latter two populations returning a small number of clones containing methylated sequences (Supplemental Fig.  1B ), indicating that a proportion of these cells may be contaminating activated Tcons. Similar findings regarding ex-FOXP3 T cells have recently been observed in mice (21) ; however, to our knowledge, this is the first demonstration in humans of a T cell population displaying a decoupling of TSDR demethylation from stable FOXP3 protein expression.
We also investigated the differentially methylated region at the FOXP3 promoter (10) and similar to P2 Tregs, both P1 and P3 Tregs displayed demethylation at this region (Supplemental Fig.  1C ). Interestingly, Tcons also displayed considerable demethylation at several CpG positions, but, as reported by Janson et al. (10) , the 277 position was discriminatory with 50% methylation in Tcons compared with ,10% in P1-P3 Tregs.
Using an in vitro culture system, we confirmed that activation of Tcons does not promote significant demethylation in T cells regardless of FOXP3 expression levels. In vitro-generated CD25 hi FOXP3 lo and CD25 hi FOXP3 hi cells both showed high levels of methylation (Supplemental Fig. 2 ).
P3 T cells display phenotypic characteristics of an activated Treg
We further examined the phenotype of the three putative Treg populations by assessing intracellular CTLA-4 expression (Fig. 3A) . P2 and P3 Tregs exhibited significantly higher levels of total 
CTLA-4 compared with CD127
hi T cells at the inflamed site whereas, interestingly, P1 Tregs exhibited an intermediate level of CTLA-4, which was significantly lower than that of P2 Tregs.
Based on high CD25 and CTLA-4 expression, as well as a demethylated TSDR but low FOXP3 expression, we hypothesized that P3 Tregs may represent a chronically activated FOXP3 lo Treg phenotype. The marker PD-1 can be expressed on chronically stimulated CD8 T cells and is associated with T cell exhaustion in HIV-infected individuals (22) . We therefore determined the expression levels of PD-1. Whereas PD-1 expression on all SF CD127 lo CD25
hi cells was significantly higher than on controls (Fig. 3B) , we observed significantly higher levels of PD-1 on the P3 Tregs compared with P1, P2, or CD127 hi T cells (Fig. 3C ).
P3 Tregs display a modest functional inferiority compared with P2 Tregs
To examine the regulatory potential of the FOXP3 lo cells observed at the site of inflammation, we required a way to separate viable cells. We hypothesized that higher levels of PD-1 could facilitate the separation of the CD25 hi population into FOXP3 hi and FOXP3 lo populations in the patient samples displaying the biggest differences in PD-1 median fluorescence intensity (MFI) between the two Treg populations. Additionally, during postsort purity analyses we noted that P3 Tregs had higher forward light scatter (FSC) characteristics than did P2 Tregs. We therefore developed a sort strategy to separate the CD25 hi population into FOXP3 hi and FOXP3 lo populations (Figs. 4, 5A, Supplemental Fig. 3A) , enabling an estimation of their functional capacities. To validate that this sort strategy did enrich for TSDR demethylated T cells, TSDR analysis was performed on cells from patient 21 (Fig. 5B) . Postsort expression of CD25, FOXP3, and PD-1 were also analyzed. Significant differences were found in PD-1 MFI (.8-fold, as expected) and FOXP3 MFI (.4-fold, as predicted), but not in CD25 expression (Fig. 5C, 5D ).
P2-and P3-enriched Tregs were tested for their ability to inhibit Tcon proliferation (Fig. 5E-G ) and cytokine secretion (Fig. 5H ) at a range of Treg/Tcon ratios. Both subsets significantly suppressed Tcon proliferation at a 1:2 ratio of Tregs to Tcons (Fig. 5E, 5F ). Titration of Tregs suggested that the suppressive capacity of P3-enriched Tregs was lower than that of P2 at the lower Treg/Tcon ratio of 1:8; however, the differences between P2 and P3 did not reach statistical significance (p = 0.0787 [paired t test] at a 1:8 ratio, Fig. 5G ).
Supernatants from these cultures were analyzed for levels of IFN-g, IL-17A, and TNF-a by cytokine multiplex assay. Both P2-and P3-enriched Tregs suppressed IFN-g and TNF-a production to a similar degree; however, there was a significant difference in the suppression of IL-17A at the 1:8 Treg/Tcon ratio (p = 0.0215) between P2 and P3 Tregs (Fig. 5H) . Given the recent reports that FOXP3 protein downregulation can lead to a de-repression of cytokine genes, such as IL-2 (20), we investigated cytokine production by P1-P3 Tregs (Supplemental Fig. 3B, 3C ). We found no difference in latency-associated peptide expression, but IL-2-and IL-17A-producing cells were slightly increased in frequency in P3 Tregs when compared with P2, which in part could have contributed to the differences in the suppression of IL-17A secretion.
Of note, P2-enriched Tregs maintained their FOXP3 hi phenotype during the in vitro culture, and interestingly P3-enriched Treg FOXP3 protein levels remained significantly lower (FOXP3 MFI at 1:2 ratio of 2433.5 versus 799.8 for P2 versus P3 Tregs, p , 0.01).
Defective IL-2 signaling in P3 Tregs
Our results suggested that high FOXP3 expression is not essential for the capacity of T cells to act as regulators, but that it may be important for optimal suppression. We next explored possible mechanisms to explain the loss of FOXP3 expression in P3 Tregs.
Two recent studies have highlighted a previously unappreciated role for the ubiquitin pathway in regulating FOXP3 expression (20, 23) . We hypothesized that if posttranslational mechanisms were dominant in regulating FOXP3 protein levels, then mRNA levels for FOXP3 should be comparable between P2 and P3 Tregs; alternatively, if transcriptional regulation were the primary mechanism, then FOXP3 transcript levels should be significantly lower in P3 versus P2 Tregs. Analysis of expression levels of FOXP3 in P2-and P3-enriched Treg populations showed that FOXP3 protein levels and relative FOXP3 mRNA expression were both significantly lower in P3-enriched Tregs (Fig. 6A ). This finding, however, did not exclude the possibility that posttranslational mechanisms may also play a role in regulating FOXP3. The deubiquitinase USP7 is upregulated in Tregs and prolongs the half-life of FOXP3 protein by reducing its ubiquitin-mediated degradation rate (20) . We measured the levels of USP7 mRNA by RT-PCR (Fig. 6B ) and flow cytometry (Fig. 6C ) and found that P3 Tregs exhibited a significantly lower level of USP7 compared with healthy control or P2 Tregs. To assess whether protein degradation was an important factor in generating the P3 phenotype, we cultured P3-enriched Tregs with the proteasome inhibitor MG132: however, we observed no increase in FOXP3 staining after culture in MG132, which may be in part due to the toxicity of MG132 to SF Tregs (Fig. 6D) . These findings collectively suggest that maintenance of USP7 expression may be important for optimal FOXP3 expression at the inflamed site, but that proteasomal degradation alone may not explain the FOXP3 lo phenotype. We next considered the transcriptional regulation of FOXP3 expression. The importance of IL-2 in maintaining FOXP3 expression is well established (24) . Because both P2 and P3 Tregs expressed high levels of CD25, we hypothesized that both should be able to respond to IL-2. We determined whether IL-2 exposure would be sufficient to recover FOXP3 expression in P3 Tregs. Both P2-and P3-enriched Tregs were sorted from SF and cultured for 24 h with or without IL-2, and expression of CD25 and FOXP3 was analyzed (Fig. 7A, 7B ). P2-enriched Tregs displayed a modest increase in FOXP3 expression and a positive shift in CD25 expression in response to IL-2; however, P3-enriched Tregs showed no increase in FOXP3 levels and a nonuniform increase in CD25 expression. The observation of this bimodal response to IL-2, as well as a previous report that Tregs in patients with autoimmunity can display defective IL-2 signaling (25), led us to hypothesize that a proportion of P3 Tregs may have a defect in signaling in response to IL-2. We therefore examined IL-2-induced STAT5 phosphorylation in SF T cells (Fig. 7C, 7D) .
SFMCs from JIA patients were cultured with IL-2 before analysis (Fig. 7C, 7D ). P2 and P1 cells exhibited robust responses to IL-2 with .90% of cells responding, as indicated by phosphorylation of STAT5 (Fig. 7C) . In contrast, P3 cells exhibited a median 65.8% response, which was significantly lower than the P1 or P2 Tregs, and even had a trend to lower STAT5 phosphorylation levels than did Tcons (median, 79.15%; Fig. 7D, left) . Levels of p-STAT5 protein quantified by MFI followed the same significant patterns (Fig. 7D, right) .
Given the critical role for IL-2 in promoting Treg homeostasis, we hypothesized that P3 Tregs would display diminished turnover in vivo. Both P1 and P2 Treg populations had a significantly higher rate of turnover compared with CD127 hi T cells (median frequencies: P1, 21.00%; P2, 23.60%; CD127 hi , 3.65%) whereas P3 exhibited intermediate turnover (median frequency, 9.28%), which was not significantly different from Tcons (Fig. 7E) , suggesting that defects in IL-2 sensitivity may result in a failure to maintain FOXP3 expression and reduced proliferative potential for P3 Tregs.
Increased proportions of P3 Tregs in the more severe forms of childhood arthritis
To understand the clinical significance of P3 Tregs, we next analyzed the frequency of the Treg populations in control subjects as well as peripheral blood and SF of patients with JIA. All three populations were significantly increased in frequency in the inflammatory compartment compared with controls or JIA PBMCa, although P1 and P3 SF Treg frequencies displayed non-Gaussian distributions (Fig. 8A) .
We next investigated whether the proportions of FOXP3 lo Tregs within the CD25 hi T cell compartment had any relationship to disease severity in JIA. It has been previously demonstrated that the milder form of oligoarticular JIA (O-JIA), called persistent O-JIA, is associated with an increased frequency and number of Tregs in the inflamed compartment (5, 6) compared with the more severe forms of disease; however, these studies did not stratify according to FOXP3 high or low expression. We observed a significantly increased proportion of FOXP3 lo T cells within the CD127 lo CD25 hi T cell compartment in patients with more severe disease (median, 31.97 versus 22.92%, p = 0.0239) when the samples were split according to the disease severity at the time of sampling (severe, polyarticular disease course; mild, persistent 
Discussion
The stability of the FOXP3 + Treg lineage has been a controversial issue for some time. We have demonstrated that high levels of CD25 and FOXP3 coexpression successfully identify committed and functional Tregs, even at the site of inflammation; however, within the CD25 hi population there is a notable decoupling of TSDR demethylation from FOXP3 expression in a subset of cells. Our data strongly support the case that this CD25 hi FOXP3 lo TSDR demethylated population is a FOXP3
lo Treg population that we speculate may have downregulated FOXP3 in the inflammatory environment.
Another striking feature of this study is the considerable heterogeneity in Treg subsets that is present at the inflamed site in humans. Whereas PBMCs show more discrete clusters, it is clear that the proportions of P1-P3 Tregs vary considerably between individuals, as well as each subset displaying its own heterogeneity within (notably P3 Tregs). A possible explanation for this is that the cells may arise from differing local environments within the joint or may be in differing stages of activation.
One unifying feature, however, of P1-P3 Tregs is that they are predominantly CD127 lo , which is interesting given the observations that some Tregs can upregulate CD127 upon activation in mice (26) . In our hands, a common theme is that the joint environment promotes a downregulation of CD127 and a concomitant upregulation of CD25. Indeed, factors that govern the expression at the inflamed site of these receptors warrants further investigation, given the importance of common g-chain cytokines to T cell survival.
Our data demonstrate that the P1 and P3 phenotypes are largely confined to the inflamed envrionment. One limitation when working with human SF is the absence of an appropriate biological control. The joints of healthy individuals are largely acellular, and ethical implications preclude the removal of SF from healthy controls. It will be interesting to compare across other diseases, including both autoimmune and nonautoimmune inflammatory disorders, as to whether the P3 Treg is a consequence of chronic inflammation, or is particular to autoimmunity. Furthermore, although this study has focused on P3 Tregs, it is clear that CD25
lo Tregs (P1) are also of interest and worth investigating. Such cells have been reported in the blood of lupus patients (27, 28) , and therefore further work is required to understand the co-regulation of CD25 and FOXP3 expression on Tregs, and how this may become dysregulated. We would hypothesize from our data that P1 Tregs represent a P2 Treg population that has downregulated CD25 expression.
It is increasingly clear that the maintenance of high FOXP3 expression in Tregs is complex and dependent on multiple factors. Undoubtedly epigenetic modifications are important players in determining the stable commitment of Tregs; in this case, the TSDR status (11, 12, 29) has been widely used to define stable FOXP3 + Tregs. Although it is known that epigenetic programming of Tregs is essential for their development (29) , our data show that TSDR demethylation alone is not sufficient in itself to maintain high FOXP3 protein expression, and other factors affecting both transcription and protein stability are defective in a subpopulation of CD25
hi Tregs. The observed loss of FOXP3 protein expression in Tregs does not necessarily support the conclusion that the entire Treg program is intrinsically "unstable" at the inflamed site, but reflects the complexity of the regulation of FOXP3 expression, and also that a Treg is more than just a FOXP3-expressing cell (29) . P3 Tregs display many characteristics of Tregs, and as such we do not think that they represent an ex-Treg population, but speculate that they may represent a FOXP3 + Treg that has downregulated FOXP3 but retains many features of Tregs, including the ability to suppress immune responses. Although in this study we cannot prove that P3 Tregs have previously expressed FOXP3, the concept of an ex-FOXP3 T cell has been reported in mice (30) , and such cells can re-express FOXP3 following culture in vitro (21) . The authors suggested that epigenetic modifications to the FOXP3 locus might serve to maintain Treg lineage commitment by imprinting memory for FOXP3 (and thus Treg commitment) regardless of ongoing FOXP3 expression. Our findings are consistent with these observations, because TSDR and promoter demethylated human FOXP3 lo Tregs still displayed suppression in vitro. Furthermore, fate mapping in mice has shown that, at the very least, a clear subset of the Treg lineage maintains stable FOXP3 transcription, even under inflammatory conditions (31) . Most fate-mapping studies, however, have deployed genetic constructs that use transcriptional readout for FOXP3 expression, and they cannot be solely relied upon to predict FOXP3 protein stability. Recent insight into the posttranslational control of FOXP3 protein may explain reported differences in studies investigating Treg FOXP3 expression stability, as several groups have documented that inflammatory insults, such as LPS challenge, IL-6, or CCL3, can trigger the ubiquitination and degradation of FOXP3 protein, which can downmodulate Treg function without affecting FOXP3 gene expression (20, 23, 32) . Analysis of these Treg populations by transcriptional methods alone would have failed to identify this downregulation of FOXP3 protein.
The in vivo consequences of human Treg FOXP3 downregulation are difficult to gauge since the studies of human Treg suppression are largely limited to the in vitro setting. Our data suggest that although P3 Tregs are suppressive in an ex vivo culture system, their performance in vivo may be compromised, as increased proportions of FOXP3 lo Tregs are found in patients with more severe disease course of JIA. It is clear from the literature that many immune cell populations displaying robust in vitro suppressive capacity are unable to regulate in vivo, where factors in addition to FOXP3 stability, such as cellular migration, turnover, Ag specificity, and survival, are likely to be important. To this end, there is a great need to develop more sophisticated assays to investigate human Treg function.
We observed that P3 Tregs displayed reduced sensitivity to IL-2 signals, and this in part may explain why IL-2 stimulation was insufficient to recover FOXP3 protein levels in these cells despite the well-known report that IL-2 is critical for maintaining Treg FOXP3 expression (24) . Defects in IL-2 signaling have been observed in patients with autoimmunity and have been attributed to increased expression of the phosphatase PTPN2 (25) . In our hands, experiments involving the phosphatase inhibitor sodium vanadate did not alter IL-2 signaling in P3 Tregs (D. Bending, unpublished observation), and the mechanisms behind this disruption in STAT5 responsiveness is of interest given that IL-2 is important not only in supporting FOXP3 expression but also for Treg proliferation and survival. Although P2 Treg turnover at the inflamed site is significantly higher than that of Tcons, as previously reported (33) , it is tempting to speculate that defects in IL-2 signaling may also render P3 Tregs hypoproliferative, and the inability of FOXP3 lo Tregs to proliferate and upregulate FOXP3 in vivo may affect their capacity to adequately respond to and control autoimmune responses. This has important ramifications for strategies deploying adoptive Treg therapies to treat inflammatory disorders, because transferred TSDR-demethylated Tregs may lose FOXP3 under conditions of stress or inflammation. It will be essential to further clarify the precise mechanisms by which Tregs can lose FOXP3 expression to optimize therapeutic strategies.
Past evidence in JIA suggests that the more severe form of oligoarthritis (extended O-JIA) is associated with a reduced frequency of Tregs compared with the milder form of disease (5, 6) . Clinical subtype analysis performed on all the SF samples in our study revealed a significant correlation between the frequency of FOXP3 lo Tregs within the CD25 hi T cell population and disease course. We therefore hypothesize that the local environment may play a critical role in regulating FOXP3 expression at inflamed sites, and that some Tregs may downregulate FOXP3. We suggest that the P3 Treg phenotype is analogous to a recently described ex-FOXP3 Treg subset identified in experimental autoimmune encephalomyelitis (30) . It would be in keeping with murine experiments that downregulation of FOXP3 in Tregs results in reduced regulation and worsened disease, as evidenced experimentally in models of type 1 diabetes, where Treg ablation leads to almost immediate onset of disease (34) . Gleaning a greater knowledge regarding the nature of, and mechanisms involved in, cells that lose FOXP3 in vivo will aid in our understanding of how Tregs may fail to function adequately in disease settings.
We have described in the present study that stable FOXP3 expression is decoupled from TSDR demethylation in a population of joint-infiltrating Tregs in human arthritis, and that the proportional representation of such cells within the Treg subset correlates with disease severity. Given the growing evidence that downregulation or loss of FOXP3 in Treg populations is detrimental to the control of chronic inflammation (20, 23, 34) , future work should try to clarify the mechanisms that occur in vivo to regulate CD25 and FOXP3 expression. A detailed understanding of these processes may yield new and unexpected therapeutic avenues to exploit for the treatment of debilitating autoimmune diseases, such as JIA.
